Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.36
- Piotroski Score 2.00
- Grade Buy
- Symbol (BMEA)
- Company Biomea Fusion, Inc.
- Price $6.61
- Changes Percentage (3.67%)
- Change $0.23
- Day Low $6.25
- Day High $6.74
- Year High $22.74
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/03/2025
- Fiscal Year End N/A
- Average Stock Price Target $20.00
- High Stock Price Target $40.00
- Low Stock Price Target $11.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.55
- Trailing P/E Ratio -1.17
- Forward P/E Ratio -1.17
- P/E Growth -1.17
- Net Income $-117,255,000
Income Statement
Quarterly
Annual
Latest News of BMEA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Biomea Fusion, Inc. (BMEA): Why Did Analysts Give This Biotech Penny Stock a Moderate Buy Rating?
A list of top biotech penny stocks includes Biomea Fusion, Inc. (NASDAQ:BMEA), a company developing treatments for cancers and metabolic diseases. Despite setbacks, BMEA shows potential for growth wit...
By Yahoo! Finance | 4 months ago -
Why Are Hedge Funds Shorting Biomea Fusion, Inc. (BMEA)?
Short selling is when assets are borrowed and sold to profit from price declines. Hedge funds often engage in short selling to protect their interests. Despite risks, short selling benefits market eff...
By Yahoo! Finance | 4 months ago -
Biomea Fusion, Inc. (NASDAQ:BMEA) Downgraded by Barclays
Analysts lowered ratings for various stocks, including Biomea Fusion, Inc. due to FDA's clinical hold on BMF-219 trials. Despite setbacks, some analysts remain optimistic about the company's long-term...
By Yahoo! Finance | 5 months ago
